^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline

Published date:
09/29/2023
Excerpt:
PRRT for SSTR-positive tumors, chemotherapy (eg, CAPTEM), everolimus, or sunitinib are recommended as second- or later-line therapy for patients with G1-G2 panNETs, with choice of therapy depending on patient characteristics and goals of treatment…